Abstract
Fatty acid synthesis is a coordinated process involving multiple enzymes. Overexpression of some of these enzymes plays important roles in tumor growth and development. Therefore, these enzymes are attractive targets for cancer therapies. Antisense agents provide highly specific inhibition of the expression of target genes and thus have served as powerful tools for gene functional studies and potential therapeutic agents for cancers. This article reviews different types of antisense agents and their applications in the modulation of fatty acid synthesis. Patents of antisense agents targeting fatty acid synthetic enzymes are introduced. In addition, miR-122 has been shown to regulate the expression of fatty acid synthetic enzymes, and thus antisense agent patents that inhibit miR-122 expression are also discussed.
Keywords: Acetyl-CoA carboxylase, antisense nucleotide, ATP citrate lyase, fatty acid synthesis, fatty acid synthetase, lipogenesis, miRNA-122, siRNAs
Recent Patents on Anti-Cancer Drug Discovery
Title:Antisense Technologies Targeting Fatty Acid Synthetic Enzymes
Volume: 7 Issue: 2
Author(s): Jinshun Lin, Feng Liu and Yuyang Jiang
Affiliation:
Keywords: Acetyl-CoA carboxylase, antisense nucleotide, ATP citrate lyase, fatty acid synthesis, fatty acid synthetase, lipogenesis, miRNA-122, siRNAs
Abstract: Fatty acid synthesis is a coordinated process involving multiple enzymes. Overexpression of some of these enzymes plays important roles in tumor growth and development. Therefore, these enzymes are attractive targets for cancer therapies. Antisense agents provide highly specific inhibition of the expression of target genes and thus have served as powerful tools for gene functional studies and potential therapeutic agents for cancers. This article reviews different types of antisense agents and their applications in the modulation of fatty acid synthesis. Patents of antisense agents targeting fatty acid synthetic enzymes are introduced. In addition, miR-122 has been shown to regulate the expression of fatty acid synthetic enzymes, and thus antisense agent patents that inhibit miR-122 expression are also discussed.
Export Options
About this article
Cite this article as:
Lin Jinshun, Liu Feng and Jiang Yuyang, Antisense Technologies Targeting Fatty Acid Synthetic Enzymes, Recent Patents on Anti-Cancer Drug Discovery 2012; 7 (2) . https://dx.doi.org/10.2174/157489212799972945
DOI https://dx.doi.org/10.2174/157489212799972945 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Personalised Genetic Intervention for Duchenne Muscular Dystrophy: Antisense Oligomers and Exon Skipping
Current Molecular Pharmacology TRP Channels and Cancer: New Targets for Diagnosis and Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Effects of Compounds from Passiflora edulis Sims f. flavicarpa Juice on Blood Coagulation and on Proteolytic Enzymes
Protein & Peptide Letters Association of Gag Multimers with Filamentous Actin During Equine Infectious Anemia Virus Assembly
Current HIV Research Using Cytokines to Treat Cervical Intraepithelial and Invasive Neoplasia
Recent Patents on Anti-Cancer Drug Discovery Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers
Current Drug Targets Current Strategies to Target the Anti-Apoptotic Bcl-2 Protein in Cancer Cells
Current Medicinal Chemistry Pharmacologic Ovarian Preservation in Young Women Undergoing Chemotherapy
Current Medicinal Chemistry The AICD Interacting Protein DAB1 is Up-Regulated in Alzheimer Frontal Cortex Brain Samples and Causes Deregulation of Proteins Involved in Gene Expression Changes
Current Alzheimer Research Liposome-Nanogel Structures for Future Pharmaceutical Applications
Current Pharmaceutical Design Biosafety of Gene Therapy Vectors Derived From Herpes Simplex Virus Type 1
Current Gene Therapy Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) Thymic Nurse Cells Participate in Heterotypic Internalization and Repertoire Selection of Immature Thymocytes; Their Removal from the Thymus of Autoimmune Animals May be Important to Disease Etiology
Current Molecular Medicine JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases
Current Drug Targets Receptor Tyrosine Kinases as Target for Anti-Cancer Therapy
Current Pharmaceutical Design Inhibitors for Metastasis Development
Recent Patents on Anti-Cancer Drug Discovery “Letting the Air In” Can Set the Stage for Tumor Recurrences
Current Cancer Therapy Reviews Isoindole Derivatives: Propitious Anticancer Structural Motifs
Current Topics in Medicinal Chemistry Nanocarrier based Antiretroviral Drug Delivery Approaches
Pharmaceutical Nanotechnology Targeting Glioblastoma: The Current State of Different Therapeutic Approaches
Current Neuropharmacology